Does the HCM Risk-SCD model accurately predict sudden cardiac death risk to target implantable cardioverter defibrillator therapy in patients with hypertrophic cardiomyopathy?
The 2014 ESC HCM Risk-SCD model is externally validated as an accurate prognostic tool for identifying hypertrophic cardiomyopathy patients who would benefit from ICD therapy.
This study confirms that the HCM Risk-SCD model provides accurate prognostic information that can be used to target implantable cardioverter defibrillator therapy in patients at the highest risk of SCD.
O’Mahony et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: